DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
Table 3
Correlations between clinicopathological features and response status in 60 locally advanced rectal cancer patients.
Characteristics
Total cases
Nonresponse
Response
value
(%)
(%)
(%)
Gender
Female
26 (43.3%)
7 (33.3%)
19 (48.7%)
0.251
Male
34 (56.7%)
14 (66.7%)
20 (51.3%)
Age (years)
<60
22 (36.7%)
8 (38.1%)
14 (35.9%)
0.886
≥60
38 (63.3%)
13 (61.9%)
25 (64.1%)
Tumor size
<5 cm
46 (76.7%)
14 (66.7%)
32 (82.1%)
0.179
≥5 cm
14 (23.3%)
7 (33.3%)
7 (17.9%)
Stage (UICC)a
II
12 (20.0%)
5 (23.8%)
7 (17.9%)
0.737
III
48 (80.0%)
16 (76.2%)
32 (82.1%)
Clinical T-stage
T3
54 (90.0%)
19 (90.5%)
35 (89.7%)
1.000
T4
6 (10.0%)
2 (9.5%)
4 (10.3%)
Clinical N-stage
N0
12 (20.0%)
5 (23.8%)
7 (17.9%)
0.846
N1
23 (38.3%)
8 (38.1%)
15 (38.5%)
N2
25 (41.7%)
8 (38.1%)
17 (43.6%)
Chemotherapy
Capecitabine
36 (60.0%)
10 (47.6%)
26 (66.7%)
0.151
5-FU
24 (40.0%)
11 (52.4%)
13 (33.3%)
Time intervals of CCRT to operation
<6 weeks
20 (33.3%)
8 (38.1%)
12 (30.8%)
0.566
( weeks)
≥6 weeks
40 (66.7%)
13 (61.9%)
27 (69.2%)
( weeks)
Differentiationb
WD
2 (3.3%)
0 (0.0%)
2 (5.1%)
0.653
MD
47 (78.3%)
17 (81.0%)
30 (76.9%)
PD
4 (6.7%)
2 (9.5%)
2 (5.1%)
Unclassified
7 (11.7%)
2 (9.5%)
5 (12.8%)
Distance to anus
<5 cm
38 (63.3%)
11 (52.4%)
27 (69.2%)
0.196
≥ 5 cm
22 (36.7%)
10 (47.6%)
12 (30.8%)
Vascular invasion
Yes
52 (86.7%)
18 (85.7%)
34 (87.2%)
1.000
No
8 (13.3%)
3 (14.3%)
5 (12.8%)
Perineural invasion
Yes
40 (66.7%)
10 (47.6%)
30 (76.9%)
0.022
No
20 (33.3%)
11 (52.4%)
9 (23.1%)
Pre-CCRT CEA
>2.5 ng/mL
44 (73.3%)
15 (71.4%)
29 (74.4%)
0.807
≤2.5 ng/ml
16 (26.7%)
6 (28.6%)
10 (25.6%)
Pre-CCRT CEAc
>5 ng/mL
27 (45.0%)
10 (47.6%)
17 (43.6%)
0.765
≤5 ng/mL
33 (55.0%)
11 (52.4%)
22 (56.4%)
Chipd result
Negative
21 (35.0%)
17 (81%)
4 (10.3%)
<0.001
Positive
39 (65.0%)
4 (19%)
35 (89.7%)
UICC: The American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC, 2002).
bWD: well differentiated, MD: moderately differentiated, PD: poorly differentiated.
cCEA: carcinoembryonic antigen.
dChip: panel of multiple genetic biomarkers.